Treatment of acute hepatitis C: the success of monotherapy with (pegylated) interferon  | Zendy

Johannes Wiegand | Zendy; Katja Deterding | Zendy; Markus Cornberg | Zendy; Heiner Wedemeyer | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Treatment of acute hepatitis C: the success of monotherapy with (pegylated) interferon

Author(s) -

Johannes Wiegand,

Katja Deterding,

Markus Cornberg,

Heiner Wedemeyer

Publication year - 2008

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkn346

Subject(s) - medicine , pegylated interferon , hepatitis , interferon , disease , liver disease , immunology , intensive care medicine , hepatitis c , chronic hepatitis , virus , ribavirin

Early control in the acute phase of hepatitis C infection is an attractive therapeutic goal in order to shorten disease duration and infectivity, to prevent chronicity and progression to advanced liver disease and to avoid eventual therapeutic non-response in the later stages of chronic hepatitis C. Over the past decade, different interferon-based treatment options have been developed, which lead to sustained virological response rates of up to 98%. The present article summarizes the successful invention of immediate and delayed strategies in acute hepatitis C monoinfection, critically discusses potential limitations and illustrates the therapeutic challenges of the near future.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research